IP Library Patent Application 15694279
Patent Application
App. No. 15/694,279

REAGENTS USEFUL FOR SYNTHESIZING RHODAMINE-LABELED OLIGONUCLEOTIDES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/694,279
Abstract

The present disclosure provides reagents that can be used to label synthetic oligonucleotides with rhodamine dyes or dye networks that contain rhodamine dyes.

Claims (40)

1 - 66 . (canceled)

67 . An oligonucleotide comprising a label moiety that comprises an N-protected NH-rhodamine moiety.

68 . The oligonucleotide of claim 67 in which the N-protected NH-rhodamine moiety comprises a structure selected from:

wherein LM represents a label moiety, PEP represents the phosphate ester precursor group, B represents a suitably protected nucleobase, L 2 represents a linker linking label moiety LM to nucleobase B and, in structure (IX.4), R 11 represents a protecting group.

69 . The oligonucleotide of claim 68 in which L 2 is selected from —C≡C—CH 2 —NH—, —C≡C—C(O)—, —CH═CH—NH—, —CH═CH—C(O)—, —C≡C—CH 2 —NH—C(O)—(CH 2 ) 1-6 —NH—, —CH═CH—C(O)—NH—(CH 2 ) 1-6 —NH—C(O)—, —C≡CH—CH 2 —O—CH 2 CH 2 —[O—CH 2 CH 2 ] 0-6 —NH—, —C≡C—C≡C—CH 2 —O—CH 2 CH 2 —[O—CH 2 CH 2 ] 0-6 —NH—, —C≡C—(Ar) 1-2 —C≡C—CH 2 —O—CH 2 CH 2 —[O—CH 2 CH 2 ] 0-6 —NH—, —C≡C—(Ar) 1-2 —O—CH 2 CH 2 —[O—CH 2 CH 2 ] 0-6 —NH— and —C≡C—(Ar) 1-2 —O—CH 2 CH 2 —[O—CH 2 CH 2 ] 0-6 —NH—, where each Ar represents, independently of the others, an optionally substituted monocyclic or polycyclic cycloalkylene, cycloheteroalkynene, arylene or heteroarylene group.

69 . The oligonucleotide of claim 68 in which —B-L 2 - is selected from

70 . The oligonucleotide of claim 68 in which the N-protected NH-rhodamine moiety comprises a structure selected from structural formulae (IIIc), (IIIb) and (IIIc):

wherein:

R′ is selected from R 3′ and hydrogen;

R″ is selected from R 6′ and hydrogen;

R 9 is an acyl protecting group;

R 1′ , R 2′ , R 2″ , R 4′ , R 4″ , R 5′ , R 5″ , R 7′ , R 7″ , R 8′ , R 4 , R 5 , R 6 , and R 7 , when taken alone, are each, independently of one another, selected from hydrogen, lower alkyl, (C6-C14) aryl, (C7-C20) arylalkyl, 5-14 membered heteroaryl, 6-20 membered heteroarylalkyl, —R b and —(CH 2 ) x —R b , where x is an integer ranging from 1 to 10 and R b is selected from —X, —OH, —OR a , —SH, —SR a , —NH 2 , —NHR a , —NR c R c , —N + R c R c R c , perhalo lower alkyl, trihalomethyl, trifluoromethyl, —B(OH) 3 , —B(OR a ) 3 , —B(OH)O − , —B(OR a ) 2 O − , —B(OH)(O − ) 2 , —B(OR a )(O − ) 2 , —P(OH) 2 , —P(OH)O − , —P(OR a ) 2 , —P(OR a )O − , —P(O)(OH) 2 , —P(O)(OH)O − , —P(O)(O − ) 2 , —P(O)(OR a ) 2 , —P(O)(OR a )O − , —P(O)(OH)(OR a ), —OP(OH) 2 , —OP(OH)O − , —OP(OR a ) 2 , —OP(OR a )O − , —OP(O)(OH) 2 , —OP(O)(OH)O − , —OP(O)(O − ) 2 , −OP(O)(OR a ) 2 , —OP(O)(OR a )O − , —OP(O)(OR a )(OH), —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R a , —C(O)H, —C(O)R a , —C(S)X, —C(O)O − , —C(O)OH, —C(O)NH 2 , —C(O)NHR a , —C(O)NR c R c , —C(S)NH 2 , —C(O)NHR a , —C(O)NR c R c , —C(NH)NH 2 , —C(NH)NHR a , and —C(NH)NR c R c , where X is halo, each R a is, independently of the others, selected from lower alkyl, (C6-C14) aryl, (C7-C20) arylalkyl, 5-14 membered heteroaryl and 6-20 membered heteroarylalkyl, and each R c is, independently of the others, an R a , or, alternatively, two R c bonded to the same nitrogen atom may be taken together with that nitrogen atom to form a 5- to 8-membered saturated or unsaturated ring that may optionally include one or more of the same or different ring heteroatoms, which are typically selected from O, N and S,

or, alternatively, R 1′ and R 2′ or R 7′ and R 8′ are taken together with the carbon atoms to which they are bonded to form an optionally substituted (C6-C14) aryl bridge and/or R 4′ and R 4″ and/or R 5′ and R 5″ are taken together with the carbon atoms to which they are bonded to form a benzo group; and

R 3′ and R 6′ , when taken alone, are each, independently of one another, selected from lower alkyl, (C6-C14) aryl, (C7-C20) arylalkyl, 5-14 membered heteroaryl and 6-20 membered heteroarylalkyl, or alternatively, R 3′ and R 2′ or R 4′ and/or R 6′ and R 5′ or R 7′ in the compounds of structural formula (IIIa), R 3′ and R 2′ or R 4′ and/or R 6′ and R 5′ or R 7″ in the compounds of structural formula (III6), or R 3′ and R 2″ or R 4′ and/or R 6′ and R 5′ or R 7″ in the compounds of structural formula (IIIc) are taken together with the atoms to which they are bonded to form a 5- or 6-membered saturated or unsaturated ring which is optionally sutstituted with one or more of the same or different lower alkyl, benzo or pyrido groups,

with the proviso that at least one of R 2′ , R 4′ , R 5′ , R 7′ , R 5 or R 6 in the compounds structural formula (IIIa), at least one of R 2′ , R 4′ , R 5′ , R 7″ , R 5 or R 6 in the compounds of structural formula (IIIb) and at least one of R 2″ , R 4′ , R 5′ , R 7″ , R 5 or R 6 in the compounds of structural formula (IIIc) comprises a group of the formula —Y—, where Y represents a portion of a linkage contributed by a functional group F y .

71 . The oligonucleotide of claim 70 , in which the N-protected NH-rhodamine moiety comprises a structure selected from structural formulae (IIIa.1), (IIIa.2), (IIIb.1), (IIIb.2), (IIIc.1) and (IIIc.2):

wherein R′, R″, R 1′ , R 2′ , R 2″ , R 3′ , R 4′ , R 4″ , R 5′ , R 5″ , R 6′ , R 7′ , R 7″ , R 4 , R 5 , R 6 , R 7 , R 8′ , R 9 and Y are as previously defined in claim 70 .

72 . The oligonucleotide of claim 70 in which the N-protected NH-rhodamine moiety has one or more applicable features selected from:

(i) Y is selected from —C(O)—, —S(O) 2 —, —S— and —NH—;

(ii) R 4 and R 7 are each chloro;

(iii) R 1′ and R 8′ are each hydrogen;

(iv) R 1′ and R 2′ or R 7′ and R 8′ are taken together to form a benzo group;

(v) R 2′ and R 7′ are each hydrogen or lower alkyl;

(vi) R′ is R 3′ and R″ is R 6′ ; and

(vii) R′ is R 3′ , R″ is R 6′ , and R 3′ and R 6′ are taken together with a substituent group on an adjacent carbon atom to form a group selected from —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —C(CH 3 ) 2 CH═C(CH 3 )—, —C(CH 3 ) 2 CH═CH—, —CH 2 —C(CH 3 ) 2 — and

73 . The oligonucleotide of claim 67 in which the label moiety is linked to the 3′- or 5′-hydroxyl of the oligonucleotide.

74 . The oligonucleotide of claim 67 in which the label moiety is linked to a nucleobase of the oligonucleotide.

75 . The oligonucleotide of claim 67 in which the oligonucleotide is further labeled with a donor and/or acceptor moiety for the N-protected NH-rhodamine moiety.

76 . The oligonucleotide of claim 75 in which the label moiety comprises structural formula (VI):

A-Z 1 -Sp-Z 2 -D   (VI)

wherein A represents the N-protected NH-rhodamine moiety, D represents the donor moitey, Z 1 and Z 2 , which may be the same or different, represent portions of linkages provided by linking moieties comprising a functional group F z , and Sp represents a spacing moiety.

77 . The oligonucleotide of claim 76 in which A is selected from structural formulae A.1, A.2, A.3, A.4, A.5 and A.6 and D is selected from structural formulae D.1, D.2, D.3, D.4, D.5 and D.6, or A is selected from structural formulae A.7, A.8, A.9, A.10, A.11 and A.12 and D is selected from structural formulae D.7, D.8, D.9, D.10, D.11 and D.12;

wherein:

E 1 is selected from —NHR 9 , —NR 3′ R 9 and —OR 9b ;

E 2 is selected from —NHR 9 , —NR 6′ R 9 and —OR 9b ;

R 9b is R 9 ;

Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , and Y 3b are each, independently of one another, selected from —O—, —S—, —NH—, —C(O—) and —S(O) 2 —; and

R′, R″, R 1′ , R 2″ , R 3′ , R 4′ , R 4″ , R 5′ , R 5″ , R6′, R 7′ , R 7″ , R 8′ , R 4 , R 5 , R 6 , R 7 , and R 9 are as previously defined in claim 34 , with the proviso that when E 1 and E 2 are —OR 9b , then R 1′ and R 2′ and/or R 7′ and R 8′ may only be taken together with the carbon atoms to which they are bound to form an optionally substituted (C6-C14) aryl bridge.

78 . The oligonucleotide of claim 67 in which the oligonucleotide is further labeled with a quencher moiety.

79 . The oligonucleotide of claim 67 in which the oligonucleotide is further labeled with a minor groove binding moiety.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2017
From: BENSON, SCOTT C.; ZOU, RUIMING N.; UPADHYA, KRISHNA G.; KENNEY, PAUL M.; CASSEL, JONATHAN M.
To: APPLERA CORPORATION
Reel/Frame 044321/0354 →
MERGER Recorded Dec 6, 2017
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 044321/0387 →
MERGER AND CHANGE OF NAME Recorded Dec 6, 2017
From: APPLIED BIOSYSTEMS INC.; ATOM ACQUISITION, LLC
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 044321/0404 →